23andMe, once a standout in direct-to-consumer genetic testing, has seen its momentum fade and market value fall sharply. Its setback highlights tough commercialization hurdles—costs, competition, and sustained demand—that could influence how India’s genetic-testing market grows. Yet the disruption may also open room for smarter, locally aligned offerings and stronger partnerships across healthcare.
Swipe through stories, personalise your feed, and save articles for later — all on the app.
